Physician profile
Radu Kramer
NPI 1326036898
$11,298.85
in general payments reported to CMS, 2019-2025
39 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,973 · 2020: $659 · 2021: $2,507 · 2022: $1,557 · 2023: $811 · 2024: $1,097 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,122.37 | 2019-2021 | |
| Abbvie INC. | $2,782.11 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,278.94 | 2021 | |
| Amgen INC. | $848.69 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $465.65 | 2021-2025 | Rexulti, Jynarque |
| Allergan, INC. | $313.64 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.93 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.52 | 2019-2025 | Xifaxan, Trulance |
| Eisai INC. | $238.51 | 2019-2025 | |
| Lilly USA, LLC | $197.47 | 2019-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $196.40 | 2022 | |
| Qol Medical, LLC | $132.95 | 2024 | Sucraid |
| Neurocrine Biosciences, INC. | $120.29 | 2025 | |
| Genentech USA, INC. | $113.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $81.65 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radu Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.